| # | Title | Journal | Year | Citations |
|---|
| 1 | Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study | Journal of Clinical Oncology | 2020 | 465 |
| 2 | Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis | New England Journal of Medicine | 2006 | 368 |
| 3 | Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2015 | 237 |
| 4 | Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial | Journal of the American Heart Association | 2016 | 215 |
| 5 | Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48 | Circulation | 2019 | 99 |
| 6 | Edoxaban for treatment of venous thromboembolism in patients with cancer | Thrombosis and Haemostasis | 2015 | 79 |
| 7 | Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF‐TIMI 48 | European Journal of Heart Failure | 2016 | 73 |
| 8 | All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation | Journal of Managed Care Pharmacy | 2011 | 65 |
| 9 | LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study | Annals of Oncology | 2021 | 64 |
| 10 | A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease | Journal of Hematology and Oncology | 2013 | 62 |
| 11 | Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib | Oncotarget | 2016 | 60 |
| 12 | 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 – LBA, biomarkers and immunogenicity) | Bioanalysis | 2016 | 49 |
| 13 | A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. | Journal of Clinical Oncology | 2020 | 48 |
| 14 | 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 – LBA: immunogenicity, biomarkers and PK assays) | Bioanalysis | 2017 | 47 |
| 15 | Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST Study | Hypertension Research | 2017 | 45 |
| 16 | Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy | American Journal of Physiology - Renal Physiology | 2014 | 44 |
| 17 | Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention | JACC: Cardiovascular Interventions | 2017 | 41 |
| 18 | Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I) | Lancet Neurology, The | 2019 | 37 |
| 19 | Morning Home Blood Pressure and Cardiovascular Events in Japanese Hypertensive Patients | Hypertension | 2018 | 31 |
| 20 | Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial | Journal of Clinical Oncology | 2023 | 31 |
| 21 | A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L). | Journal of Clinical Oncology | 2018 | 30 |
| 22 | Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study | Cardiovascular Diabetology | 2012 | 29 |
| 23 | Prospective observational study in elderly patients with non-valvular atrial fibrillation: Rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry | Journal of Cardiology | 2018 | 29 |
| 24 | The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease | Thrombosis and Haemostasis | 2014 | 27 |
| 25 | Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study | Hypertension Research | 2013 | 25 |
| 26 | Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies | Journal of Human Genetics | 2015 | 24 |
| 27 | LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen | Annals of Oncology | 2021 | 24 |
| 28 | Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi‐Stakeholder Think Tank | Journal of the American Heart Association | 2018 | 23 |
| 29 | Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial | American Heart Journal | 2014 | 22 |
| 30 | A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas. | Journal of Clinical Oncology | 2016 | 20 |
| 31 | Burden of Illness Associated with Tenosynovial Giant Cell Tumors | Clinical Therapeutics | 2018 | 19 |
| 32 | Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists | Thrombosis and Haemostasis | 2016 | 17 |
| 33 | Dynamic prediction model and risk assessment chart for cardiovascular disease based on on-treatment blood pressure and baseline risk factors | Hypertension Research | 2016 | 17 |
| 34 | New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk | European Heart Journal - Cardiovascular Pharmacotherapy | 2018 | 17 |
| 35 | Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice | Circulation: Cardiovascular Interventions | 2015 | 16 |
| 36 | The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design | Clinical Cardiology | 2019 | 16 |
| 37 | Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). | Journal of Clinical Oncology | 2021 | 16 |
| 38 | Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study. | Journal of Clinical Oncology | 2018 | 16 |
| 39 | Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study | BMJ Open Diabetes Research and Care | 2017 | 15 |
| 40 | Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). | Journal of Clinical Oncology | 2022 | 14 |
| 41 | Understanding the experience of living with non–small-cell lung cancer (NSCLC): a qualitative study | Journal of Community and Supportive Oncology | 2014 | 13 |
| 42 | Validation studies on blood collection from the jugular vein of conscious mice | Journal of the American Association for Laboratory Animal Science | 2012 | 13 |
| 43 | Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition | Nature Medicine | 2022 | 13 |
| 44 | Unravelling the Smokers’ Paradox: Cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors | Thrombosis and Haemostasis | 2014 | 12 |
| 45 | Impact ofUGT1A1genotype upon toxicities of combination with low-dose irinotecan plus platinum | Asia-Pacific Journal of Clinical Oncology | 2016 | 12 |
| 46 | TBA225, a fusion toxoid vaccine for protection and broad neutralization of staphylococcal superantigens | Scientific Reports | 2019 | 12 |
| 47 | Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis. | Journal of Clinical Oncology | 2020 | 12 |
| 48 | Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study) | Journal of Human Hypertension | 2013 | 11 |
| 49 | Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study | Clinical Cancer Research | 2019 | 11 |
| 50 | Differences between clinic blood pressure and morning home blood pressure, as shown by Bland–Altman plots, in a large observational study (HONEST study) | Hypertension Research | 2015 | 10 |
